GET DAILY SIGNALSElanco Animal Health (ELAN) Delivers 11.3% Revenue Growth in Strong Q3 2026
Key Takeaways
- Elanco Animal Health (ELAN) reported third-quarter 2026 revenue of $1.265 billion, up 11.3% year over year and ahead of the roughly $1.21 billion consensus estimate.
- Adjusted earnings per share (EPS) came in at $0.27, comfortably above the consensus range of $0.20–$0.21, while GAAP net income swung to $18 million from a $34 million loss a year earlier.
- Adjusted gross margin expanded 300 basis points to 56.1%, and adjusted EBITDA rose 23% to $243 million.
- Net leverage improved to 2.9x adjusted EBITDA, down from 3.6x at year-end 2025, reaching a key capital-allocation milestone ahead of schedule.
- Management raised full-year 2026 guidance, now targeting adjusted EPS of $1.17–$1.20 and revenue of approximately $5.15 billion–$5.18 billion.
Why This Quarter Matters
Elanco’s third-quarter report matters because it tests whether the company’s innovation-led turnaround can sustain momentum across both pet health and farm animal segments. The company has now beaten and raised guidance for four consecutive quarters, powered by newer products such as Zenrelia and Credelio Quattro. Strong pricing, accelerating organic growth, and a sharp improvement in gross margin signal that its “Big 6” innovation portfolio is gaining share in large, growing markets. At the same time, investors are watching whether this cycle’s peak momentum can hold into 2027, given a slower guided fourth quarter and tougher comparisons ahead. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Figures
Elanco reported third-quarter 2026 revenue of $1.265 billion, an 11.3% increase from $1.137 billion a year earlier, exceeding consensus estimates by roughly 4.8%. Organic constant-currency revenue grew 9%, led by International Pet Health up 17% and U.S. Pet Health up 13%. Price accelerated to 4% year-over-year growth while volume rose 5%.
On an adjusted basis, net income grew 45% to $136 million, or $0.27 per diluted share, topping analyst expectations of about $0.20–$0.21. Under generally accepted accounting principles (GAAP), Elanco posted net income of $18 million, or $0.04 per diluted share, compared with a net loss of $34 million, or $0.07 per share, in the prior-year period.
Adjusted EBITDA climbed 23% to $243 million, with the adjusted EBITDA margin widening to 19.5% from 17.5%. Adjusted gross margin expanded 300 basis points to 56.1%. Net leverage fell to 2.9x adjusted EBITDA, down from 3.6x at the end of 2025. Management raised its full-year outlook, lifting adjusted EPS guidance to $1.17–$1.20 and revenue guidance to approximately $5.15 billion–$5.18 billion, while raising its full-year innovation revenue target to $1.275 billion.
How the Market Responded
Elanco’s shares rose following the release, reflecting investor approval of a fourth consecutive beat-and-raise. The results were widely framed as the company’s cleanest quarterly beat since its innovation cycle began, with adjusted EPS and revenue both exceeding expectations and full-year guidance raised to pass through the outperformance. Sentiment was further supported by the earlier-than-expected achievement of the sub-3x leverage milestone, which management said unlocks greater capital-allocation flexibility. Still, some analysts noted that the quarter may mark a near-term high-water mark, with fourth-quarter organic growth guided lower and a broader set of 2027 comparisons on the horizon.
What to Watch Going Forward
Looking ahead, investors should watch whether Elanco can sustain its innovation momentum beyond the third quarter. The company is guiding fourth-quarter organic revenue growth to roughly 4%–6%, a step down from the third quarter’s pace, while operating expenses are expected to rise about 11%. This near-term deceleration is one of the key factors to monitor heading into year-end.
Product launches remain central to the story. Credelio Quattro has received a positive opinion for expansion into the European Union, with a planned first-quarter 2027 launch, and Befrena is expected to move to a full-scale U.S. launch in early 2027. Management has indicated Befrena could become the single largest contributor to U.S. Pet Health growth next year.
Margin and pricing trends also deserve attention. Elanco has flagged that price growth may normalize toward the historical 2%–3% range as launch-driven pricing eases. Finally, investors will be watching farm animal cycles, the integration of the AHV International acquisition, and whether free cash flow and leverage continue to improve in line with the company’s longer-term targets.
My Take on Using Tickeron’s AI Screener
I often turn to Tickeron’s AI Screener when evaluating names like Elanco to quickly filter for comparable companies based on fundamentals, technical patterns, and AI-driven signals. It helps surface ideas across the sector without spending hours on manual screens, giving a clearer view of relative strength and potential opportunities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for ELAN shows an upward move is likely
ELAN's Aroon Indicator triggered a bullish signal on November 05, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 207 similar instances where the Aroon Indicator showed a similar pattern. In 179 of the 207 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on ELAN as a result. In 52 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
The Moving Average Convergence Divergence (MACD) for ELAN just turned positive on October 05, 2026. Looking at past instances where ELAN's MACD turned positive, the stock continued to rise in 32 of 47 cases over the following month. The odds of a continued upward trend are 68%.
ELAN moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ELAN crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +5.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELAN advanced for three days, in 174 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
The 10-day RSI Indicator for ELAN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 23 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 50-day moving average for ELAN moved below the 200-day moving average on October 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELAN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
ELAN broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ELAN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.796) is normal, around the industry mean (7.445). P/E Ratio (-57.756) is within average values for comparable stocks, (0.293). Projected Growth (PEG Ratio) (4.042) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (2.275) is also within normal values, averaging (181.047).
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELAN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of animal food
Industry PharmaceuticalsGeneric
Advertisement